Why Praxis Precision Medicines, Inc. (PRAX) stock moved
Praxis Precision Medicines, Inc. (PRAX) shares tumbled 6.3% to $344.75 as of August 30, 2026, a significant decline from the prior close of $367.85. BestStocks flagged the session as a major change for PRAX. Below, we break down what changed for PRAX, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
PRAX fell 6.3% to $344.75
PRAX tumbled 6.3% in its latest session, moving from $367.85 to $344.75.
What it means for Praxis Precision Medicines, Inc. investors
For Praxis Precision Medicines, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Praxis Precision Medicines, Inc. (PRAX) moved +2.53% from $357.90 to $366.96 on 2026-08-10; Praxis Precision Medicines, Inc. (PRAX) moved +4.41% from $304.43 to $317.87 on 2026-07-21. Weighing against that: Material negative event; Sharp 6.3% decline — elevated risk. Wall Street's consensus price target sits at $603.83, implying +75.2% upside from $344.75. BestStocks rates the overall signal quality low (55/100). With earnings roughly 71 days out, the next report is the most likely near-term test of the move.
PRAX price reaction
PRAX last traded at $344.75, down $23.10 (-6.28%) from the previous close of $367.85. The session traded on 0.6× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $305.51 and $386.33, and it currently sits about 49% of the way up that band.
Bullish and bearish analyst opinions on Praxis Precision Medicines, Inc. (PRAX)
The consensus analyst price target on Praxis Precision Medicines, Inc. (PRAX) is $603.83, 75.2% above the recent $344.75. Over the past 90 days analysts logged 0 upgrades, 13 maintains, and 0 downgrades. Here is how the bullish and bearish cases on PRAX line up.
The bullish case
- Wall Street's consensus price target of $603.83 implies +75.2% upside from $344.75.
- The Street's most bullish target is $1,201.00 (+248.4%).
- Praxis Precision Medicines, Inc. (PRAX) moved +2.53% from $357.90 to $366.96 on 2026-08-10.
The bearish case
- The most bearish analyst target is $162.00 (-53.0%).
- Material negative event.
- Sharp 6.3% decline — elevated risk.
- Praxis Precision Medicines, Inc. (PRAX) moved -3.17% from $314.41 to $304.43 on 2026-07-20.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Aug 30, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for PRAX
Frequently asked questions about PRAX
Why did Praxis Precision Medicines, Inc. (PRAX) stock move?
PRAX tumbled 6.3% to $344.75. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did PRAX stock fall?
PRAX lost 6.28% ($23.10) versus the prior close of $367.85, last trading at $344.75 on 0.6× average volume.
When is Praxis Precision Medicines, Inc.'s next earnings date?
PRAX's next earnings report is estimated for 2026-11-09 — about 71 days away.
What is the analyst price target for PRAX?
The consensus analyst price target for PRAX is $603.83, about 75.2% above the current $344.75. Over the past 90 days, analysts recorded 0 upgrades, 13 maintains, and 0 downgrades.
How BestStocks tracks PRAX
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared PRAX-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for PRAX, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of August 30, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.